Kathleen N. Moore
University of Southern California(US)Gynecologic Oncology Group(US)University of Wyoming(US)International Fund for Animal Welfare(US)Oklahoma City University(US)Christchurch Hospital(NZ)University of Oklahoma Medical Center(US)The Netherlands Cancer Institute(NL)Opexa Therapeutics (United States)(US)Sarah Cannon(US)Florida Cancer Specialists & Research Institute(US)Oklahoma State University Oklahoma City(US)MD Anderson Cancer Center Madrid(ES)OU HealthOU Health Stephenson Cancer CenterUniversity of Oklahoma Health Sciences Center(US)University of Cincinnati(US)University of Oklahoma(US)Vanderbilt University Medical Center(US)University of Cincinnati Medical Center(US)
Publications by Year
Research Areas
Ovarian cancer diagnosis and treatment, PARP inhibition in cancer therapy, Endometrial and Cervical Cancer Treatments, Cancer Immunotherapy and Biomarkers, Cervical Cancer and HPV Research
Most-Cited Works
- → Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer(2018)2,759 cited
- → Recent advances and clinical applications of deep learning in medical image analysis(2022)944 cited
- → Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer(2019)912 cited
- → Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma(2019)545 cited
- → Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial(2019)522 cited
- → Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial(2022)446 cited